This disclosure provides a generalized approach for engineering receptor tyrosine kinases (RTKs) optically controlled with far-red light, named eDrRTKs, by targeting a bacterial phytochrome (e.g., DrBphP) to the cell surface and allowing its light-induced conformational changes to be transmitted across the plasma membrane via transmembrane helices to intracellular RTK domains. The ability to activate eDrRTKs with far-red light enabled cross-talk free spectral multiplexing with fluorescent probes operating in a shorter spectral range, allowing for all-optical assays, including non-invasive stimulation in the brain of a live animal. The disclosed engineering approach can be applied beyond RTKs to any membrane receptors, channels, surface antigens, or membrane antibodies that share high similarity with RTKs in mechanisms of their activation.
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/5377 - 1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 35/02 - Antineoplastic agents specific for leukemia
Provided are anti-human Tim-3 IgV domain-specific antibodies and fragments thereof, as well as methods of use employing such antibodies and/or fragments.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
Methods of preventing or treating a coronavirus infection or a herpes simplex virus infection in a subject or preventing or treating a disease caused by a coronavirus infection or a herpes simplex virus infection in a subject are disclosed. The methods comprise administering to the subject an effective amount of a cell-impermeable inhibitor comprising a cell-impermeable kinase inhibitor, a cell-impermeable Akt inhibitor, an anti-Akt antibody, a cell-impermeable 3-phosphoinositide-dependent protein kinase-1 (PDPK1) inhibitor, an anti-PDPK1 antibody, or a combination thereof.
A61K 31/553 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Provided herein are methods of modifying immune cell activity by altering KJR2DL5 expression and/or activity. The methods, which include administering to a subject one or more agents that decrease KJR2DL5 expression and/or activity, increase immune cell function, and treat diseases such as cancer and infectious diseases.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/00 - Medicinal preparations containing antigens or antibodies
Disclosed herein are phenylethanolamine n-methyltransferase (PNMT) inhibitors to regulate adrenaline responses. The inhibitors exhibit high specificity for PNMT over other DNA and protein methyltransferases. Also disclosed are pharmaceutical compositions of the inhibitors and methods of treating various diseases associated with associated with dysregulated epinephrine production.
A61K 31/7076 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
Disclosed herein are mitofusin inhibitors which are capable of inducing mitochondrial fission, decreasing mitochondrial respiration, TCA metabolism, and inducing mitochondrial outer membrane permeabilization that leads to caspase activation and DNA damage signaling. Also disclosed are methods of treating diseases or conditions associated with imbalanced mitochondrial dynamics.
Disclosed herein are small molecule activators of the B-cell lymphoma-2-associated X protein (BAX). Also disclosed are compositions containing one or more BAX activators and uses thereof in the treatment of cancer.
A transdermal formulation for the delivery of one or more active agents to a subject is provided. The formulation can be applied to the treatment of various diseases or conditions associated with an elevated CD38 level.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
This disclosure provides novel neutralizing and potent antibodies targeting S100 proteins, related nucleic acids, related cells, related kits, related compositions, and related methods or uses.
C07K 16/24 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
A61P 35/02 - Antineoplastic agents specific for leukemia
Disclosed herein are mitofusin inhibitors which are capable of inducing mitochondrial fission, decreasing mitochondrial respiration, TCA metabolism, and inducing mitochondrial outer membrane permeabilization that leads to caspase activation and DNA damage signaling. Also disclosed are methods of treating diseases or conditions associated with imbalanced mitochondrial dynamics.
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
A61K 31/196 - Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
C07C 215/50 - Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups bound to carbon atoms of at least one six-membered aromatic ring and amino groups bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups linked to the six-membered aromatic ring, or to the condensed ring system containing that ring, by carbon chains not further substituted by hydroxy groups with amino groups and the six-membered aromatic ring, or the condensed ring system containing that ring, bound to the same carbon atom of the carbon chain
C07C 233/88 - Carboxylic acid amides having nitrogen atoms of carboxamide groups bound to an acyclic carbon atom and to a carbon atom of a six-membered aromatic ring wherein at least one ortho-hydrogen atom has been replaced
C07C 235/56 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
12.
LOW INTENSITY FOCUSED ULTRASOUND FOR TREATING CANCER AND METASTASIS
Systems and methods for treating cancer and for preventing metastasis using low intensity focused ultrasound in combination with an anti-cancer therapy are disclosed.
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
A61K 41/00 - Medicinal preparations obtained by treating materials with wave energy or particle radiation
Disclosed are kits and methods for detecting the presence of tumor sites that are active in tumor cell dissemination and uses thereof for determining the risk of tumor cells undergoing hematogenous metastasis, for assessing the prognosis of a subject undergoing treatment for a localized tumor, for determining a course of treatment for a localized tumor, and for identifying agents to treat or prevent hematogenous metastasis.
Provided herein are organoids having concentric zones of telencephalic and ocular progenitors and methods of producing these organoids. Also provided herein are retinal ganglion cells (RGCs) growing directional axons in these organoids and methods of isolating RGCs.
The present disclosure describes methods of detecting, examining, and/or screening activity of a protein (e.g., an enzyme) that binds or interacts with a genome and/or chromatin in a binding event that occurs in a live cell. The method includes performing live-cell single molecule tracking of the protein (e.g., an enzyme) in a binding event bound to the genome and/or chromatin of the cell at an image acquisition frame rate of about 300 to about 700 milliseconds/frame (e.g., about 400 to about 600 milliseconds/frame or about 500 milliseconds/frame) to generate 3 or more localization data points of binding events in the cell; and calculating the anisotropy formed between three successive localization data points. The methods of the present disclosure allow for a binding event, and activity during the same, of a protein to be examined.
Compounds, compositions and method of using these compounds are disclosed for treating a disease or disorder in which it is desirable to inhibit BAX, such as a cardiovascular disease or disorder.
A61K 31/496 - Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
C07D 209/86 - CarbazolesHydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
C07D 209/88 - CarbazolesHydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
C07D 279/26 - [b, e]-condensed with two six-membered rings with carbon atoms directly attached to the ring nitrogen atom with hydrocarbon radicals, substituted by amino radicals, attached to the ring nitrogen atom without other substituents attached to the ring system
C07D 295/13 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
18.
METHOD OF TREATING AND/OR PREVENTING TYPE 1 DIABETES WITH CEPHARANTHINE
This disclosure provides methods of treating and/or preventing type 1 diabetes (T1D) and/or a syndrome including type 1 diabetes and autoimmune thyroiditis in a subject. The methods include administering a therapeutically effective amount of cepharanthine or a pharmaceutically acceptable salt, solvate or derivative thereof to the subject, wherein the subject has a human leucocyte antigen class II, DR3 allele (HLA-DR3) genotype.
A61K 31/4741 - QuinolinesIsoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
A61K 31/551 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogens as ring hetero atoms, e.g. clozapine, dilazep
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
A61K 31/277 - NitrilesIsonitriles having a ring, e.g. verapamil
A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
A61K 31/429 - Thiazoles condensed with heterocyclic ring systems
A61K 31/437 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
A61K 31/4985 - Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
A61K 31/506 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
20.
COMPOSITIONS AND METHODS FOR INHIBITING THE EXPRESSION OF TMIGD2
Methods of treating cancer by inhibiting TMIGD2 expression and/or activity are provided herein. In some embodiments, the methods comprise administering one or more of: (a) a TMIGD2 mRNA targeting agent, (b) a gene-based therapeutic agent, (c) a small molecule TMIGD2 inhibitory molecule, or (d) a TMIGD2 antibody or antigen-binding fragment thereof to inhibit TMIGD2 expression and/or activity in a subject in need thereof.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
A61K 39/00 - Medicinal preparations containing antigens or antibodies
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
THE GOVERNMENT OF THE UNITED STATES, AS REPRESENTED BY THE SECRETARY OF THE ARMY (USA)
Inventor
Walker, Laura M.
Wec, Anna Z.
Guardado-Calvo, Pablo
Rey, Felix A.
Mittler, Eva
Chandran, Kartik
Bradfute, Steven B.
Abelson, Dafna M.
Herbert, Andrew S.
Dye, John
Abstract
Provided herein are hantivirus antibodies. These hantivirus antibodies bind to the Gn and/or Gc subunits of a hantavirus glycoprotein and have broad neutralizing activity against an epitope of different hantavirus species. Such antibodies are used in methods of inducing an immune response and methods of inhibiting hantavirus infection. Additionally provided are methods of treating an infectious disease using such antibodies.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
ALBERT EINSTEIN COLLEGE OF MEDICINE (USA)
Inventor
Gorbunova, Vera
Seluanov, Andrei
Suh, Yousin
Abstract
An isolated nucleic acid molecule encoding a variant of sirtuin 6 (SIRT6) having at least 75% identity with sequence SEQ ID NO: 1, the variant having at least one mutation selected from a N308K substitution and a A313S substitution with respect to sequence SEQ ID NO: 1. Also, means for the regulation of ageing, and/or senescence, and/or lifespan in an individual. Further, means for the repair of double strand breaks in a cell. Finally, means for the prevention and/or the treatment of an age-related disease.
Provided are methods of treating an HHLA2-bearing tumor in a subject with a fusion protein comprising an IgV-like domain of a TMIGD2 sufficient to treat the HHLA2-bearing tumor. A fusion protein comprising an IgV-like domain of a TMIGD2 and related compositions and encoding nucleic acids are also provided.
This disclosure provides the single-component near-infrared light-controlled IsPadC-PCM-based optogenetic systems for prokaryotic and eukaryotic cells, consisting of an evolved photosensory core module of the Idiomarina sp. bacterial phytochrome, named iLight. The iLight systems are smaller and packable in an adeno-associated virus, as compared to the other near-infrared optogenetic systems based on phytochromes. This disclosure demonstrates the high light-activation efficiency of the developed iLight systems in gene transcription regulation in bacteria, cultured mammalian cells, primary isolated neurons, and living mouse tissue in vivo. The iLight systems also enable crosstalk-free spectral multiplexing with optogenetic systems and fluorescent probes activated or excited by light of the visible spectral range.
Provided herein are fusion proteins comprising a single domain antibody (sdAb) (including, but not limited to, a nanobody) that binds selectively to a specific antigen, wherein a second polypeptide is inserted into the single domain antibody, generating an internal fusion. Also provided are methods of making and methods of using the fusion proteins disclosed herein.
A method for revitalizing mesenchymal stem cells (MSC) maintained in culture by transducing the MSC with vectors encoding a specific gene combination, as well as methods of use of MSC so revitalized in co-culturing hematopoictic stem cells.
Provided herein are recombinant vesicular stomatitis virus (rVSV) or rVSV vector comprising nucleic acid encoding the spike glycoprotein S of SARS-COV-2, compositions comprising such vectors or viruses, as well as screening methods, diagnostic methods, prophylactic and therapeutic methods using such vectors or viruses.
This disclosure provides a method of stabilizing the interaction of a Retinoic Acid Receptor-alpha (RARα) and a corepressor, Nuclear Receptor Corepressor 1 (NCoR1) by contacting the RARa with an amount of a Chaperone Mediated Autophagy (CMA) Activator sufficient to stabilize the RARα-NCoR1 interaction. Stabilizing the RARα/corepressor interaction can prevent a neurodegenerative disorder in a subject at risk for developing the neurodegenerative disorder or slow the advancement of a neurodegenerative disorder in a subject having an early symptom or biomarker of the neurodegenerative disorder. The disclosure also provides a method of maintaining preventing or slowing the advancement of a retinal degenerative disorder in a subject having an early symptom or biomarker of the retinal degenerative disorder. The neurodegenerative disorder can be Alzheimer's disease (AD), Lewy body dementia, Parkinson's disease (PD), Huntington's disease, Amyotrophic lateralsclerosis (ALS), Frontotemporal dementia (FTD), Spinocerebellar ataxias (SCAs). The retinal degenerative disorder can be retinitis pigmentosa.
A61K 31/538 - 1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
As described herein, binding of the B7-1 protein with the neuronal cell surface p75 neurotrophin receptor protein triggers loss of synaptic connections. Methods and compositions are also described for treatment of neurological diseases and conditions (including pain) and for identifying therapeutic agents useful for treatment of neurological diseases and conditions (including pain).
The disclosure provides method of enhancing neuronal, vascular cell, and macrophage proteostasis, in a subject by administering a CMA activator to the subject. Enhancing proteostasis is a method of preventing or slowing advancement of an age-related neurodegenerative disease, atherosclerosis, or an inflammatory disease in a subject. The age related neurodegenerative disease can be Alzheimer A disease (AD), Lewy body dementia, Parkinson's disease (PD), Huntington's disease, Amyotrophic lateral sclerosis (ALS), Frontotemporal dementia (FTD). Spinocerebellar ataxias (SC As), or Progressive subcortical gliosis. The disclosure further provides a method of reducing the progression of beta-amyloid and/or tau pathology in the subject, and/or reduces pre-existing beta-amyloid and/or tau pathology in the subject.
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
A61P 25/28 - Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
34.
CLINICAL DECISION SUPPORT SYSTEMS EMPLOYING REVERSE PHENOTYPING
Clinical decision support systems employing reverse phenotyping. In various embodiments, genomic information of a patient is read from a datastore. One or more variant of the genomic information is determined. The one or more variant is associated with a disease state. One or more phenotypic features are determined, associated with the one or more variant. A healthcare provider is prompted to evaluate the patient for the one or more phenotypic features.
G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
G16B 20/20 - Allele or variant detection, e.g. single nucleotide polymorphism [SNP] detection
G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
35.
Use of Chaperone-Mediated Autophagy Activators For Treating Or Preventing Blood Cancers And Myelodysplastic Syndromes And Enriching Hematopoietic Stem Cell Populations
The present disclosure provides methods of treating disease and disorders of the hematological system. The disclosure provides a method of expanding a population of hematopoietic stem cells (HSCs) while maintaining the population in an undifferentiated state comprising contacting the population of HSCs in the presence of a CMA activator for a period of time until a sufficient number of HSCs is obtained thereby producing an expanded HSC population.
Formulations comprising one or more active agents for blood storage and transfusions are provided. Also provided methods for prolonging viability of blood and enhancing efficacy of blood transfusion.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
G06T 19/00 - Manipulating 3D models or images for computer graphics
A61B 5/00 - Measuring for diagnostic purposes Identification of persons
A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations
A61B 90/00 - Instruments, implements or accessories specially adapted for surgery or diagnosis and not covered by any of the groups , e.g. for luxation treatment or for protecting wound edges
G06T 7/62 - Analysis of geometric attributes of area, perimeter, diameter or volume
G06T 7/68 - Analysis of geometric attributes of symmetry
G06T 7/73 - Determining position or orientation of objects or cameras using feature-based methods
G06T 19/20 - Editing of 3D images, e.g. changing shapes or colours, aligning objects or positioning parts
G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
38.
THROMBOPOIETIN MIMETIC FOR USE IN THE TREATMENT OF ACUTE LIVER FAILURE
A method of treating patients suffering from acute liver failure is disclosed. The method comprises administering to a patient in need of treatment an effective amount of a thrombopoietin (TPO) compound alone or combined with another agent as described in the specification. A method of treating patients suffering from acetaminophen overdose is also disclosed. The method comprises administering to a patient in need of treatment an effective amount of a TPO compound alone or combined with another agent as described in the specification.
A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
39.
RNA TAGGING SYSTEM FOR VISUALIZATION OF SINGLE MRNA MOLECULES
Provided are high affinity Mycobacterium tuberculosis arabinomannan-specific antibodies and antigen-binding fragments thereof. Also provided are methods of use and devices employing such Mycobacterium tuberculosis arabinomannan-specific antibodies and antigen-binding fragments thereof.
Provided are antibodies and antigen-binding fragments thereof binding to Mycobacterium tuberculosis arabinomannan, to GroEL2, or to LprG, as well as methods of use and devices employing such antibodies and/or antigen-binding fragments.
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/498 - Pyrazines or piperazines ortho- or peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
A61K 31/517 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
Provided herein are polypeptides, compositions, and methods for treating a cancer in an individual using a polypeptide comprising a thrombopoietin domain and a Flt3 ligand domain. Also provided herein are nucleic acids encoding such polypeptides, expression vectors and cells comprising such nucleic acids, and methods of producing the polypeptides comprising a thrombopoietin domain and a Flt3 ligand domain. The administration of a fusion polypeptide comprising a thrombopoietin domain and a Flt3 ligand domain to a subject may treat and reduce the symptoms of hematopoietic failure, including thrombopenia, and/or acute radiation syndrome.
Persistence and linking of analytic products is provided. Information regarding a plurality of analytic methods is collected. A first process node is generated in a network. The first process node corresponds to a first analytic method. Information is collected regarding a plurality of executions of the first analytic method. A plurality of session nodes is generated in the network corresponding to the plurality of executions. Each of the plurality of session nodes is linked to the first process node. Metadata regarding the plurality of executions is associated with the plurality of session nodes. At least one product node is generated corresponding to a product. The product integrates a result value of at least one of the plurality of executions. The at least one product node is linked to the session node of the plurality of session nodes corresponding to the at least one of the plurality of executions.
A transdermal formulation for the delivery of one or more active agents to a subject is provided. The formulation can be applied to the treatment of various diseases or conditions associated with an elevated CD38 level.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/366 - Lactones having six-membered rings, e.g. delta-lactones
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
This disclosure provides novel compounds and methods for inhibiting BAX activity and BAX-mediated apoptosis, as well as compounds and methods for treating or preventing BAX-mediated disorders.
C07D 231/46 - Oxygen atom in position 3 or 5 and nitrogen atom in position 4
C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
A device for generating nitric oxide is disclosed. The device is configured for applying to either a body cavity or a surface of a subject in need thereof. Also disclosed is a method for the treatment of diseases or conditions with the device.
A herpes simplex virus (HSV) gene vaccine and expression vector and/or vaccine vector comprising an HSV genome comprising: a complete deletion of glycoprotein G-encoding gene, glycoprotein J-encoding gene, glycoprotein D-encoding gene, and glycoprotein I-encoding gene; a heterologous nucleic acid comprising an expression cassette and inserted in a region of the genome from which the glycoprotein G-encoding gene, glycoprotein J-encoding gene, glycoprotein D-encoding gene, and glycoprotein I-encoding gene have been deleted; an attL sequence; and an attR sequence, wherein the attL sequence is adjacent to a first end of the expression cassette and the attR sequence is adjacent to a second end of the expression cassette, and wherein the expression cassette comprises in operable communication a promoter and at least one gene encoding a heterologous protein.
A composition and a kit comprising a nitrite source admixed with a gelling agent for nitric oxide production. Also disclosed is a method for generating nitric oxide, which finds applications in the treatment of various diseases.
A transdermal formulation for the delivery of a nitric oxide booster or nitric oxide precursor to a subject is provided. The formulation can be applied to the treatment of various diseases or conditions by enhancing systemic level of nitric oxide.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
51.
NEOADJUVANT CHEMOTHERAPY INDUCES BREAST CANCER METASTASIS THROUGH A TMEM-MEDIATED MECHANISM
Methods of reducing chemotherapy-induced metastasis, or chemotherapy-induced cancer cell dissemination, for patients subject to chemotherapy using Tie-2 inhibitors. Methods of reducing chemotherapy-induced metastasis, or chemotherapy-induced cancer cell dissemination, for patients subject to chemotherapy using inhibitors of Mena expression and/or function are also provided.
The present technology provides chimeric antigen receptors (CARs) comprising a TMIGD2 costimulatory domain. In certain embodiments, these CARs comprise an intracellular region comprising the TMIGD2 costimulatory domain and an effector domain, a transmembrane domain, and an extracellular region comprising an antigen binding domain and, optionally a hinge region and/or leader sequence. In other embodiments, these CARs comprise an intracellular region comprising the TMIGD2 costimulatory domain and an effector domain, a transmembrane domain, and an extracellular region comprising an antigen binding domain which specifically binds to tumor associated antigen B7-H3, and, optionally a hinge region and/or leader sequence. Also provided are nucleic acids, vectors, and cells relating to these CARs, as well as methods of using the CARs, nucleic acids, vectors, and cells in the treatment of conditions associated with expression of specific antigens.
Johannes Gutenberg University (JGU) Medical Center (Germany)
Inventor
Tomer, Yaron
Faustino, Larissa C.
Kahaly, George J.
Abstract
Methods of predicting response of a subject in need of immunosuppressant therapy to a Cluster of differentiation 40 (CD40)-targeted treatment are disclosed. The methods permit treating the subject with a treatment most likely to show a favorable response.
C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
54.
High resolution intravital imaging and uses thereof
Provided herein is a novel platform for engineered antigen-binding proteins (e.g., bispecific antigen-binding proteins, e.g., single-domain bispecifics) called ODIN (Orthogonal Dual-Interacting Nanotherapeutics). The platform is useful in generating a wide range of engineered antigen-binding proteins.
A recombinant herpes simplex virus 2 (HSV-2) vaccine vector including a complete deletion of the gene encoding glycoprotein D and its promoter is described, and methods for producing virus and virions of the recombinant HSV-2 in transgenic Vero cells expressing HSV-1 glycoprotein D are provided. Compositions including the recombinant HSV-2 and methods of using the compositions are also provided.
Compositions and methods are provided for reducing NPM1 glutamate-glutamylation and for treating cancers characterized by overexpression of TTLL4 and/or expression of a mutant NPM1.
C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
C12Q 1/68 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving nucleic acids
C07H 21/00 - Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
C12Q 1/25 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving enzymes not classifiable in groups
HACKENSACK MERIDIAN HEALTH CENTER FOR DISCOVERY AND INNOVATION (USA)
Inventor
Spivack, Simon, D.
Shi, Miao, Kevin
Abstract
Provided herein are compositions and methods for detecting exhaled microRNAs for identifying lung diseases such as cancer, asthma, and chronic obstructive pulmonary disease.
G01N 33/497 - Physical analysis of biological material of gaseous biological material, e.g. breath
A61B 10/00 - Instruments for taking body samples for diagnostic purposesOther methods or instruments for diagnosis, e.g. for vaccination diagnosis, sex determination or ovulation-period determinationThroat striking implements
C12Q 1/6809 - Methods for determination or identification of nucleic acids involving differential detection
A reporter mycobacteriophage comprising a heterologous nucleic acid comprising a promoter-reporter construct encoding a promotor operably linked to a nucleotide sequence encoding a fusion protein, wherein the fusion protein comprises a luciferase protein linked to a fluorescent protein. Methods of utilizing the reporter mycobacteriophage in detection of a viable target microbe in a sample, screening a test substance for treatment of tuberculosis, and detecting a drug-resistant Mycobacterium in a subject are provided.
C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
C12N 15/62 - DNA sequences coding for fusion proteins
This disclosure is based, at least in part, on the unexpected discovery that genetically modified pluripotent stem cells having a constitutively active stem cell factor (SCF) can differentiate into enucleated red blood cells, self-renew, and expand in culture media for an extended period of time. Accordingly, the disclosed methods enable large-scale production of red blood cells with significantly reduced overall cost as compared to the existing methods.
A pharmaceutical combination comprising a B-cell lymphoma 2 associated X protein (BAX) activating compound an anti-apoptotic protein inhibiting compound is provided. The disclosure also provides a method of treating cancer in a subject by administering a B-cell lymphoma 2 associated X protein (BAX) activating compound in combination with an anti-apoptotic protein inhibiting compound, such as a BCL-XL, BCL-2, BFL-1. BCL-w, or MCL-1 inhibiting compound.
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
62.
METHODS OF TREATING VIRAL INFECTIONS WITH PiRNAS OR EXTRACELLULAR VESSICLES RELEASED FROM NEURAL STEM CELLS OR NEURAL PROGENITOR CELLS
Described herein are methods of treating an individual in need of treatment or prevention of infection with a virus including administering to the individual a therapeutically effective amount of extracellular vesicles released from neural stem cells and/or neural progenitor cells, or administering to the individual a therapeutically effective amount of a composition including one or more piRNAs, wherein the piRNAs have a perfect match with a sense or antisense sequence of the genome of the virus in a primary lead sequence at positions 2-8. Also included are compositions including the piRNAs.
Polypeptides, nucleic acids, and compositions thereof are provided that include a targeting moiety. The polypeptides, nucleic acids, and compositions that comprise them, can be used in methods to treat subjects, to alter CAR-expressing cells in subjects who may suffer from a disease such as a cancer or a pathogen.
A61K 39/00 - Medicinal preparations containing antigens or antibodies
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
64.
Mycobacterium tuberculosis capsule-specific human monoclonal antibody
Mycobacterium tuberculosis capsule-specific antibodies and fragments thereof, as well as methods of use and devices employing such antibodies and/or fragments.
Methods for treating or preventing diseases and conditions associated with Clostridium difficile infection are provided. The methods effectively inhibit bacterial pathogens induced UDP-glucose hydrolysis activity with minimized damage to host tissue.
C12Q 1/6872 - Methods for sequencing involving mass spectrometry
A61K 31/53 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
A composition and method for treatment of opioid use disorder (OUD) is provided by expressing a novel mu receptor mutant, LAMuOR (Low Affinity Mu Opioid Receptor), with reduced binding affinity for opioids such that it is activated only by the high concentration of exogenous opioids encountered in OUD but not by the low concentrations of endogenous opioids that occur physiologically. When expressed in specific brain circuits, these low- affinity mu opioid receptors can suppress reward-related neuronal activity specifically in the presence of opioids of abuse, thereby reducing abuse potential.
This disclosure provides compounds and pharmaceutically acceptable salts thereof of Formula I (Formula I) The variables, e.g. R1-R4, and Z are defined herein. Y is Y is (II). Certain compounds of Formula I are highly potent against resistant tumor cell el lines driven by BRAFV600E monomer melanoma cells (A375 or SK-MEL-239), p61-BRAFV600E dimer splice variant melanoma cells (SK-MEL-239-C4) and colorectal (RKO) and lung cancer (A549) cells, and at the same time display a highly desirable pharmacological profile in a mice tumor model.
This disclosure provides compounds and pharmaceutically acceptable salts thereof of Formula I (Formula I) The variables, e.g. R1-R4, and Z are defined herein. Y is Y is (II). Certain compounds of Formula I are highly potent against resistant tumor cell el lines driven by BRAFV600E monomer melanoma cells (A375 or SK-MEL-239), p61-BRAFV600E dimer splice variant melanoma cells (SK-MEL-239-C4) and colorectal (RKO) and lung cancer (A549) cells, and at the same time display a highly desirable pharmacological profile in a mice tumor model.
C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
C07D 417/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing three or more hetero rings
69.
HERPES VIRUS ENTRY MEDIATOR PROTEINS AND METHODS OF USE THEREOF
inter aliainter alia, are compositions including herpes virus entry mediator (HVEM) proteins and fragments thereof. The HVEM proteins provided herein may have modulated binding affinity to ligands and/or receptors compared to wild type HVEM proteins. The HVEM proteins provided herein are contemplated to be effective for treating diseases, particularly cancer and inflammatory diseases.
This disclosure provides methods for inhibiting BAX activity and BAX-mediated apoptosis, as well as methods for treating or preventing BAX-mediated disorders, based, in part, on an unexpected discovery that eltrombopag (EO) can work as as a potent binder to the BAX trigger site and an effective direct BAX inhibitor.
A61K 31/4152 - 1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
A61K 31/635 - Compounds containing para-N-benzene- sulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonohydrazide having a heterocyclic ring, e.g. sulfadiazine
A transdermal formulation for the delivery of a nitric oxide booster or nitric oxide precursor to a subject is provided. The formulation can be applied to the treatment of various diseases or conditions by enhancing systemic level of nitric oxide.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
73.
METHODS AND COMPOSITIONS FOR ASSESSING GERMLINE RISK OF CANCER
Heritable mutations in the BRCA1 and BRCA2 and other genes in the DNA double-strand break (DSB) repair pathway increase risk of breast, ovarian and other cancers. In response to DNA breaks, the proteins encoded by these genes bind to each other and are transported into the nucleus to form nuclear foci and initiate homologous recombination. Flow cytometry-based functional variant analyses (FVAs) were developed to determine whether variants in BRCA1 or other DSB repair genes disrupted the binding of BRCA1 to its protein partners, the phosphorylation of p53 or the transport of the BRCA1complex to the nucleus in response to DNA damage. Each of these assays distinguished high-risk BRCA1 mutations from low-risk BRCA1 controls. Mutations in other DSB repair pathway genes produced molecular phenocopies with these assays. FVA assays may represent an adjunct to sequencing for categorizing VUS or may represent a stand-alone measure for assessing breast cancer risk.
G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer
C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
74.
CHARACTERIZATION OF S-ADENOSYL-L-METHIONINE-CONSUMING ENZYMES WITH 1-STEP EZ-MTASE: A UNIVERSAL COUPLED-ASSAY
Methods and kits are disclosed for measuring activity of a methyltransferase or a radical SAM enzyme or for screening for an inhibitor of a methyltransferase or a radical SAM enzyme, where the methods and kits comprise, respectively, deaminase TM0936 for a MTase coupled assay and deaminase PA3170 for a radical SAM coupled assay.
C12Q 1/48 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving transferase
C12Q 1/34 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase
Antibodies and antibody fragments that inhibit the activity of vascular cell adhesion molecule 1 (VCAM1) and/or macrophage erythroblast attacher (MAEA) are provided, along with formulations and kits comprising these antibodies and antibody fragments and the use of the disclosed compositions, formulations, and kits to treat cancers, sickle cell disease, and Polycythemia Vera.
C07K 16/00 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
A61P 7/00 - Drugs for disorders of the blood or the extracellular fluid
A61P 35/02 - Antineoplastic agents specific for leukemia
C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
C07K 16/30 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
e.g.e.g., DrBphP) to the cell surface and allowing its light-induced conformational changes to be transmitted across the plasma membrane via transmembrane helices to intracellular RTK domains. The ability to activate eDrRTKs with far-red light enabled cross-talk free spectral multiplexing with fluorescent probes operating in a shorter spectral range, allowing for all-optical assays, including non-invasive stimulation in the brain of a live animal. The disclosed engineering approach can be applied beyond RTKs to any membrane receptors, channels, surface antigens, or membrane antibodies that share high similarity with RTKs in mechanisms of their activation.
Disclosed herein are mitofusin inhibitors which are capable of inducing mitochondrial fission, decreasing mitochondrial respiration, TCA metabolism, and inducing mitochondrial outer membrane permeabilization that leads to caspase activation and DNA damage signaling. Also disclosed are methods of treating diseases or conditions associated with imbalanced mitochondrial dynamics.
A61K 31/165 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
A61K 31/167 - Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen atom of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
C07C 233/64 - Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
A method of replacing endogenous microglia of a subject’s brain, e.g., an adult subject, with transplanted donor microglia includes depleting at least a portion of the endogenous microglia by administering to the subject a Colony Stimulating Factor 1 Receptor (CSFR1) inhibitor, wherein the CSFR1 inhibitor is blood-brain barrier permeable and pharmacologically ablates endogenous microglia; optionally stopping administration of the CSFR1 inhibitor for a time sufficient to prevent ablation of the transplanted donor microglia; and transplanting the donor microglia into the brain of the subject to provide the transplanted donor microglia.
C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
79.
METHOD FOR MEASURING SOMATIC DNA MUTATION AND DNA DAMAGE PROFILES AND A DIAGNOSTIC KIT SUITABLE THEREFORE
Disclosed are compositions and methods related to detecting rare mutations (e.g., somatic mutations) or genome structure variants using rolling circle-based linear amplification and next generation sequencing.
Disclosed are compositions and methods related to detecting rare mutations (e.g., somatic mutations) or genome structure variants using rolling circle-based linear amplification and next generation sequencing.
Methods of preventing or treating a coronavirus infection or a herpes simplex virus infection in a subject or preventing or treating a disease caused by a coronavirus infection or a herpes simplex virus infection in a subject are disclosed. The methods comprise administering to the subject an effective amount of a cell-impermeable inhibitor comprising a cell-impermeable kinase inhibitor, a cell-impermeable Akt inhibitor, an anti-Akt antibody, a cell-impermeable 3- phosphoinositide-dependent protein kinase- 1 (PDPK1) inhibitor, an anti-PDPKl antibody, or a combination thereof.
Provided herein are methods of modifying immune cell activity by altering KIR2DL5 expression and/or activity. The methods, which include administering to a subject one or more agents that decrease KIR2DL5 expression and/or activity, increase immune cell function, and treat diseases such as cancer and infectious diseases.
This disclosure relates to contacting T cells with mitofusin activators and/or PI3K inhibitors to improve efficacy in cell therapies. In certain embodiments, this disclosure relates to methods of treating cancer comprising administering an effective amount of activated T cells using methods as disclosed herein to a subject in need thereof. In certain embodiments, the T cells express a chimeric antigen receptor.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
84.
METHODS, COMPOSITIONS, AND KITS FOR MODIFYING IMMUNE CELL ACTIVITY VIA KIR2DL5
Provided herein are methods of modifying immune cell activity by altering KIR2DL5 expression and/or activity. The methods, which include administering to a subject one or more agents that decrease KIR2DL5 expression and/or activity, increase immune cell function, and treat diseases such as cancer and infectious diseases.
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61K 39/00 - Medicinal preparations containing antigens or antibodies
85.
A METHOD TO GENERATE CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELLS (CAR-T CELLS) FROM PATHOGEN-SPECIFIC CYTOTOXIC LYMPHOCYTES TO ENABLE THE SUBSEQUENT IN VIVO MODULATION OF THEIR FUNCTIONAL ACTIVITY
The present disclosure relates to a method of modulating one or more genetically modified cells, e.g., chimeric antigen receptor (CAR)-expressing cells, ex vivo and/or in vivo.
C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A transdermal formulation for the delivery of a nitric oxide booster or nitric oxide precursor to a subject is provided. The formulation can be applied to the treatment of various diseases or conditions by enhancing systemic level of nitric oxide.
A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
A61K 31/4375 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring hetero atom, e.g. quinolizines, naphthyridines, berberine, vincamine
A61K 31/593 - 9,10-Secocholestane derivatives, e.g. cholecalciferol, vitamin D3
87.
Antagonist antibodies against human immune checkpoint CEACAM1 (CD66a) and formulations, kits, and methods of use thereof
Provided are isolated antibodies and antigen-binding fragments thereof that specifically bind CEACAM1, including the IgV domain of CEACAM1, as well as pharmaceutical formulations, kits, and methods of use thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 47/68 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
88.
METHOD OF TREATING AND PREVENTING OCULAR DISEASE WITH HSV-2 DELTA GD
Methods of treating or preventing ocular disease caused by herpes simplex virus-1 infection are provided, and comprise administering to a subject an effective amount of a herpes simplex virus-2 (HSV-2) having a deletion of an HSV-2 glycoprotein D-encoding gene in the genome to treat or prevent ocular disease in the subject, wherein the HSV-2 is phenotypically complemented with an HSV-1 glycoprotein D by propagating the HSV-2 in a complementing cell expressing the HSV-1 glycoprotein D.
Methods of increasing progenitor cell production are described. In particular, an effective amount of a thrombopoietin (TPO) mimetic is used to increase production of at least one cell selected from a stem cell, a progenitor cell or an endothelial cell in the bone marrow of non-irradiated subjects.
A device for generating nitric oxide is disclosed. The device is configured for applying to either a body cavity or a surface of a subject in need thereof. Also disclosed is a method for the treatment of diseases or conditions with the device.
Provided are methods of treating an autoimmune disease in a subject, or of suppressing transplant rejection in a subject, or of treating a cancer in a subject, as well as compositions therefor.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
92.
METHODS FOR THE GENERATION OF HUMAN RETINAL GANGLION CELLS AND COMPOSITIONS, ASSAYS, DEVICES, AND KITS COMPRISING SAME
Glaucoma is a leading cause of incurable blindness, affecting millions of people worldwide. In glaucoma, retinal ganglion cells (RGCs) progressively degenerate in subjects having or not having high intraocular pressure. Provided herein are organoids having concentric zones of telencephalic and ocular progenitors and methods of producing these organoids. Also provided herein are retinal ganglion cells (RGCs) growing directional axons in these organoids and methods of isolating RGCs.
A device for generating nitric oxide is disclosed. The device is configured for applying to either a body cavity or a surface of a subject in need thereof. Also disclosed is a method for the treatment of diseases or conditions with the device.
A composition and a kit comprising a nitrite source admixed with a gelling agent for nitric oxide production. Also disclosed is a method for generating nitric oxide, which finds applications in the treatment of various diseases.
Disclosed are compositions and methods for the preservation, storage, and transport of living biological tissues, organs, and populations of isolated cells. In particular, the compositions and methods permit mammalian cells, tissues, and organs to be recovered from suitable donor animals, stored for prolonged periods, and transported to the site of recipient implantation, all without significant loss of cell viability, biological activity, and/or tissue integrity.
A61K 31/137 - Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine
C07D 209/88 - CarbazolesHydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
C07D 295/13 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
A61P 39/00 - General protective or antinoxious agents
96.
METHOD OF TREATING AND/OR PREVENTING TYPE 1 DIABETES WITH CEPHARANTHINE
This disclosure provides methods of treating and/or preventing type 1 diabetes (T1D) and/or a syndrome including type 1 diabetes and autoimmune thyroiditis in a subject. The methods include administering a therapeutically effective amount of cepharanthine or a pharmaceutically acceptable salt, solvate or derivative thereof to the subject, wherein the subject has a human leucocyte antigen class II, DR3 allele (HLA-DR3) genotype.
A61K 31/357 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
G01N 33/569 - ImmunoassayBiospecific binding assayMaterials therefor for microorganisms, e.g. protozoa, bacteria, viruses
C07K 14/74 - Major histocompatibility complex [MHC]
C12Q 1/6881 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for tissue or cell typing, e.g. human leukocyte antigen [HLA] probes
98.
COMPOSITIONS AND METHODS OF ENRICHING HEMATOPOIETIC STEM CELL POPULATIONS AND METHODS OF USE THEREOF
Described herein are antibodies, immunogenic fragments and compositions thereof targeting the killer-cell immunoglobulin-like receptor protein KIR3DL3, as well as methods of using the same for the treatment of human diseases including cancer. In certain embodiments, the disclosure relates to an antibody or an immunogenic fragment thereof that specifically binds to KIR3DL3 protein, wherein the antibody or the immunogenic fragment thereof specifically binds to a KIR3DL3 epitope comprising the whole extracellular domain or a portion thereof.
C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K 39/395 - AntibodiesImmunoglobulinsImmune serum, e.g. antilymphocytic serum
Described herein are compositions and methods for the prevention and treatment of ebolavirus infection. In certain embodiments of the present invention, monoclonal antibodies substantially similar to those described herein, as well as affinity matured variants thereof, alone or in combination, provide therapeutic efficacy in a patient against multiple species of ebolavirus.
patents
